KR20150018832A - 전신 마취약과 수소를 조합하여 이루어지는, 의약 - Google Patents

전신 마취약과 수소를 조합하여 이루어지는, 의약 Download PDF

Info

Publication number
KR20150018832A
KR20150018832A KR20147035945A KR20147035945A KR20150018832A KR 20150018832 A KR20150018832 A KR 20150018832A KR 20147035945 A KR20147035945 A KR 20147035945A KR 20147035945 A KR20147035945 A KR 20147035945A KR 20150018832 A KR20150018832 A KR 20150018832A
Authority
KR
South Korea
Prior art keywords
anesthetic
hydrogen
general
medicament
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20147035945A
Other languages
English (en)
Korean (ko)
Inventor
도미에이 가자마
야스시 사토
류지 요나미네
Original Assignee
마루이시세이야쿠가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마루이시세이야쿠가부시키가이샤 filed Critical 마루이시세이야쿠가부시키가이샤
Publication of KR20150018832A publication Critical patent/KR20150018832A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR20147035945A 2012-05-31 2013-05-30 전신 마취약과 수소를 조합하여 이루어지는, 의약 Withdrawn KR20150018832A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012125535 2012-05-31
JPJP-P-2012-125535 2012-05-31
PCT/JP2013/065094 WO2013180240A1 (ja) 2012-05-31 2013-05-30 全身麻酔薬と、水素とを組み合わせてなる、医薬

Publications (1)

Publication Number Publication Date
KR20150018832A true KR20150018832A (ko) 2015-02-24

Family

ID=49673427

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147035945A Withdrawn KR20150018832A (ko) 2012-05-31 2013-05-30 전신 마취약과 수소를 조합하여 이루어지는, 의약

Country Status (16)

Country Link
US (1) US20150079197A1 (https=)
EP (1) EP2857026A4 (https=)
JP (1) JP6168420B2 (https=)
KR (1) KR20150018832A (https=)
CN (1) CN104394873A (https=)
AU (1) AU2013268366A1 (https=)
BR (1) BR112014029260A2 (https=)
CA (1) CA2874579A1 (https=)
HK (1) HK1205450A1 (https=)
IL (1) IL235718A0 (https=)
IN (1) IN2014MN02090A (https=)
MX (1) MX2014014543A (https=)
NZ (1) NZ701553A (https=)
RU (1) RU2014152690A (https=)
SG (1) SG11201407489TA (https=)
WO (1) WO2013180240A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6253029B2 (ja) * 2015-01-21 2017-12-27 大陽日酸株式会社 麻酔器用取付キット
US20180338995A1 (en) * 2017-05-23 2018-11-29 Perricone Hydrogen Water Company, Llc Systems and methods for treatments using hydrogen and/or noble gases
US11129848B2 (en) * 2017-08-08 2021-09-28 Perricone Hydrogen Water Company, Llc Medication enhancement using hydrogen
EP3814502A4 (en) * 2018-06-29 2022-10-05 John Mansell COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANESTHESIA-RELATED NEUROTOXICITY
US11123365B2 (en) 2019-11-18 2021-09-21 Perricone Hydrogen Water Company, Llc Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof
JP7019910B2 (ja) * 2020-07-21 2022-02-16 ＭｉＺ株式会社 薬の副作用、薬の副作用に関連する症状、および／または、治療に伴う副作用を予防および／または改善するための組成物
CN117861037A (zh) * 2022-10-11 2024-04-12 上海氢医医疗科技有限公司 氢气吸入治疗自闭症
CN119303200A (zh) * 2024-12-17 2025-01-14 山东百多安医疗器械股份有限公司 一种可以释放氢气减少神经损伤的麻醉机

Also Published As

Publication number Publication date
CN104394873A (zh) 2015-03-04
CA2874579A1 (en) 2013-12-05
MX2014014543A (es) 2015-06-05
WO2013180240A1 (ja) 2013-12-05
BR112014029260A2 (pt) 2017-06-27
SG11201407489TA (en) 2014-12-30
NZ701553A (en) 2016-06-24
IN2014MN02090A (https=) 2015-09-04
IL235718A0 (en) 2015-01-29
JPWO2013180240A1 (ja) 2016-01-21
EP2857026A4 (en) 2015-11-04
AU2013268366A1 (en) 2015-03-19
US20150079197A1 (en) 2015-03-19
JP6168420B2 (ja) 2017-07-26
EP2857026A1 (en) 2015-04-08
HK1205450A1 (en) 2015-12-18
RU2014152690A (ru) 2016-07-20

Similar Documents

Publication Publication Date Title
JP6168420B2 (ja) 全身麻酔薬と、水素とを組み合わせてなる、医薬
Ait-Bali et al. Pre-and postnatal exposure to glyphosate-based herbicide causes behavioral and cognitive impairments in adult mice: evidence of cortical ad hippocampal dysfunction
Karen et al. Effect of propofol in the immature rat brain on short-and long-term neurodevelopmental outcome
Ma et al. Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain
Desai et al. Neuropeptide Y attenuates anxiety-and depression-like effects of cholecystokinin-4 in mice
Shan et al. Dexmedetomidine ameliorates the neurotoxicity of sevoflurane on the immature brain through the BMP/SMAD signaling pathway
Cui et al. Reward ameliorates depressive-like behaviors via inhibition of the substantia innominata to the lateral habenula projection
Fujimura et al. Perinatal exposure to low-dose methylmercury induces dysfunction of motor coordination with decreases in synaptophysin expression in the cerebellar granule cells of rats
Nie et al. Propofol attenuates isoflurane-induced neurotoxicity and cognitive impairment in fetal and offspring mice
Kim et al. P2X7 receptor differentially modulates astroglial apoptosis and clasmatodendrosis in the rat brain following status epilepticus
Jiang et al. The GABAB receptor agonist STX209 reverses the autism-like behaviour in an animal model of autism induced by prenatal exposure to valproic acid
Giri et al. Pretreatment with minocycline improves neurogenesis and behavior performance after midazolam exposure in neonatal rats
Ding et al. CX3CR1 mediates nicotine withdrawal-induced hyperalgesia via microglial P38 MAPK signaling
Flores et al. Neonatal olfactory bulbectomy enhances locomotor activity, exploratory behavior and binding of NMDA receptors in pre-pubertal rats
Barr et al. Changing mechanisms of opiate tolerance and withdrawal during early development: animal models of the human experience
Harding et al. Prenatal exposure to valproic acid and treatment with intranasal oxytocin have sex-specific effects on behavior in Long Evans rats
Iida et al. Analgesic effect of linalool odor on oral ulcerative mucositis-induced pain in rats
Ribeiro et al. A single intraperitoneal injection of ketamine does not affect spatial working, reference memory or neurodegeneration in adult mice: an animal study
Kurokawa et al. Possible involvement of type 1 inositol 1, 4, 5-trisphosphate receptors up-regulated by dopamine D1 and D2 receptors in mouse nucleus accumbens neurons in the development of methamphetamine-induced place preference
Wei et al. Bumetanide attenuates sevoflurane‐induced neuroapoptosis in the developing dentate gyrus and impaired behavior in the contextual fear discrimination learning test
Sun et al. Interactions between astrocytes and neurons in the brainstem involved in restraint water immersion stress-induced gastric mucosal damage
Mooney et al. Prenatal exposure to ethanol affects postnatal neurogenesis in thalamus
Guerriero et al. Augmented constitutive CREB expression in the nucleus accumbens and striatum may contribute to the altered behavioral response to cocaine of adult mice exposed to cocaine in utero
Alphs et al. Schizophrenic Inpatients'
Al-Musawi Evidence for prodromal changes in neuronal excitability and neuroinflammation in the CA3 region of the hippocampus in young alpha-synuclein (A30P) transgenic mice and investigation of the effect of intranasal metformin treatment

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141222

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180525

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20180615

WITB Written withdrawal of application